872511-35-8

Usage

Uses

Used in Pharmaceutical Industry:
N4-(4-(4-ethylpiperazin-1-yl)phenyl)-N6-MethylpyriMidine-4,6-diaMine is used as a potential pharmaceutical agent for its ability to interact with biological targets such as receptors or enzymes. This interaction may lead to the development of new treatments for various diseases and conditions.
Used in Research Applications:
In the field of scientific research, N4-(4-(4-ethylpiperazin-1-yl)phenyl)-N6-MethylpyriMidine-4,6-diaMine serves as a valuable compound for studying the mechanisms of action and potential therapeutic effects of pyrimidine-based molecules. This can contribute to a better understanding of their role in biological processes and the development of novel drugs.

Upstream product

• 933702-18-2 (6-chloropyrimidin-4-yl)methylamine 
• 115619-01-7 4-(4-ethylpiperazin-1-yl)aniline 
• 586-78-7 para-nitrophenyl bromide 
• 115619-00-6 1-ethyl-4-(4-nitro-phenyl)-piperazine 
• 5308-25-8 4-ethylpiperazine 
• 65766-32-7 6-chloro-N-methylpyrimidin-4-amine 

Downstream Products

• 943189-14-8 3-(5-methoxy-3-trifluoromethyl-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea 
• 872511-34-7 NVP-BGJ398 

Relevant academic research and scientific papers

CHLOROBENZENE SUBSTITUTED AZAARYL COMPOUNDS

The invention provides a series of chlorobenzene substituted azaaryl compounds having activity in inhibiting cancer cell growth and low toxicity to normal cells. Particularly, the compounds of the invention have stronger inhibition effect on bladder cance

Discovery of 3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl- piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), A potent and selective inhibitor of the fibroblast growth factor receptor family of receptor tyrosine kinase

A novel series of N-aryl-N′-pyrimidin-4-yl ureas has been optimized to afford potent and selective inhibitors of the fibroblast growth factor receptor tyrosine kinases 1, 2, and 3 by rationally designing the substitution pattern of the aryl ring. On the b

CRYSTALLINE FORMS OF 3-(2,6-DICHLORO-3,5-DIMETHOXY-PHENYL)-1-{6-[4-(4-ETHYL-PIPERAZIN-1-YL)-PHENYLAMINO]-PYRIMIDIN-4-YL}-1-METHYL-UREA AND SALTS THEREOF.

The present technology provides novel anhydrous and hydrated crystalline forms of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea, amorphous and anhydrous crystalline polymorphs of its mono

PYRIMIDINYL ARYL UREA DERIVATIVES BEING FGF INHIBITORS

The invention relates to heteroaryl aryl ureas of the formula (IA), wherein the radicals and symbols have the meanings as defined herein, the use of such compounds in the treatment of protein kinase dependent diseases; to pharmaceutical preparations comprising said heteroaryl aryl ureas, to processes for the manufacture of such novel compounds and to methods of treatment comprising the use of such heteroaryl aryl ureas.

PYRIMIDINE UREA DERIVATIVES AS KINASE INHIBITORS

The invention relates to compounds of formula (I) wherein the substituents X1, R1, R2, R3 and R4 have the meaning as set forth and explained in the description of the invention, to processes for the preparation of these compounds, pharmaceutical compositions containing same, the use thereof optionally in combination with one or more other pharmaceutically active compounds for the therapy of a disease which responds to an inhibition of protein kinase activity, and a method for the treatment of such a disease.